Hydroxychloroquine sulfate
( DrugBank: Hydroxychloroquine, Hydroxychloroquine sulfate / KEGG DRUG: Hydroxychloroquine sulfate, Hydroxychloroquine, Hydroxychloroquine sulfate, Hydroxychloroquine )
5 diseases
| 告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症/視神経脊髄炎 | 1 |
| 46 | 悪性関節リウマチ | 8 |
| 48 | 原発性抗リン脂質抗体症候群 | 2 |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,898 / 薬物数 : 2,785 - (DrugBank : 360) / 標的遺伝子数 : 265 - 標的パスウェイ数 : 239
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. 悪性関節リウマチ
臨床試験数 : 4,743 / 薬物数 : 3,042 - (DrugBank : 389) / 標的遺伝子数 : 205 - 標的パスウェイ数 : 253
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
48. 原発性抗リン脂質抗体症候群
臨床試験数 : 96 / 薬物数 : 112 - (DrugBank : 22) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
53. シェーグレン症候群
臨床試験数 : 448 / 薬物数 : 436 - (DrugBank : 104) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 185
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
66. IgA腎症
臨床試験数 : 407 / 薬物数 : 342 - (DrugBank : 73) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
